effect of tobacco chewing on the efficacy of inferior alveolar nerve block in patients diagnosed with symptomatic irreversible pulpitis

assessment of the analgesic effect of premedication as a supplement to inferior alveolar nerve block in tobacco users with symptomatic irreversible pulpitis: a multicentric randomized control trial

Status

Active, not recruiting

Phases

Phase 3

Study type

Interventional

Source

CTRI

Registry ID

CTRI/2023/06/053683

Enrollment

160

Registered

2023-06-08

Start date

Unknown

Completion date

Unknown

Last updated

2025-04-07

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Health Condition 1: Z768- Persons encountering health services in other specified circumstances Health Condition 2: K040- Pulpitis

Interventions

Intervention1: ibuprofen 600mg: single dose 1 tablet of Oral premedication (Tab. Ibuprofen 600mg) one hour before injecting 2% lignocaine 1:100000 for inferior alveolar nerve block in tobacco chewing.

Eligibility

Inclusion criteria

Inclusion criteria: 1.Patients aged between 18-69 years and falling under class 1 as per the ASA Classification system. 2.Mandibular 1st and 2nd molar with symptoms of symptomatic irreversible pulpitis 3.Moderate to severe pain 4.Prolonged response to cold test after removing Endo ice-cold spray stimuli. 5.Completely formed roots without periapical radiolucency and any periodontal ligament space alterations as evaluated radiographically. 6.Willing to participate in the present trial

Exclusion criteria

Exclusion criteria: 1.Patient taking beta blockers or opioids or any NSAIDs preoperatively. 2.Pregnant/ nursing mothers. 3.Patient with known allergy to LA or any of its constituents. 4.Patient not willing to participate in the present trial.

Design outcomes

Primary

Measure	Time frame
To evaluate & compare the effect of oral premedication as a supplement to IANB in tobacco-chewing & non-tobacco-chewing patients with symptomatic irreversible pulpitis.Timepoint: Pre operative pain score to be measured before LA administration in pre medication & non pre medication group respectively EPT test to be conducted 15mins after LA administration Pain score to be measured after accessing the pulp chamber	—

Measure

Time frame

To evaluate & compare the effect of oral premedication as a supplement to IANB in tobacco-chewing & non-tobacco-chewing patients with symptomatic irreversible pulpitis.Timepoint: Pre operative pain score to be measured before LA administration in pre medication & non pre medication group respectively EPT test to be conducted 15mins after LA administration Pain score to be measured after accessing the pulp chamber

—

Secondary

Measure	Time frame
• To evaluate & compare the effect of oral premedication as a supplement to IANB in tobacco-chewing and non-tobacco-chewing patients with symptomatic irreversible pulpitis. • To evaluate and compare the effectiveness of IANB in tobacco-chewing and non-tobacco-chewing patients with symptomatic irreversible pulpitis Timepoint: Pre operative pain score to be measured before LA administration in pre medication & non pre medication group respectively EPT test to be conducted 15mins after LA administration Pain score to be measured after accessing the pulp chamber	—

Measure

Time frame

• To evaluate & compare the effect of oral premedication as a supplement to IANB in tobacco-chewing and non-tobacco-chewing patients with symptomatic irreversible pulpitis. • To evaluate and compare the effectiveness of IANB in tobacco-chewing and non-tobacco-chewing patients with symptomatic irreversible pulpitis Timepoint: Pre operative pain score to be measured before LA administration in pre medication & non pre medication group respectively EPT test to be conducted 15mins after LA administration Pain score to be measured after accessing the pulp chamber

—

Countries

India

Contacts

Public Contactsimith yadav

government medical college jalaun

simithyadav@gmail.com7839317160

Outcome results

None listed

Source: CTRI (via WHO ICTRP) · Data processed: Feb 4, 2026